|By Marketwired .||
|August 28, 2014 07:54 PM EDT||
VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 08/28/14 -- Response Biomedical Corp. ("Response" or "the Company") (TSX: RBM)(OTCBB: RPBIF) is pleased to announce that Lewis J. "Lew" Shuster has been appointed Chairman of its board of directors (the "Board"). Dr. Peter A. Thompson, the outgoing Chairman, will remain on the Board.
"Lew brings more than three decades of global life science company executive and board leadership experience to Response. He has made valuable contributions since joining the Response Board in 2011, including chairing multiple board committees as the lead independent director," stated Dr. Thompson.
"All of us associated with Response appreciate Dr. Thompson's extensive contributions to the Company since he joined the Response Board in 2010, including serving as the interim CEO during part of 2011 and 2012," noted Mr. Shuster. "We respect his need to devote additional time now to his expanded OrbiMed responsibilities since becoming a Private Equity Partner at OrbiMed last year and helping to build several new biotech companies."
Mr. Shuster joined the Board as a director and chairman of the Audit Committee in June 2011. Currently, he is the Chief Executive Officer of Shuster Capital. From 2003 to 2007 he served as CEO of Kemia Inc., a drug discovery and development company. He had previously held executive positions with Invitrogen Corporation, including Chief Operating Officer. From 1994 through to 1999, while at Pharmacopeia, Inc., Mr. Shuster served as the firm's Chief Financial Officer and later as COO of Pharmacopeia Labs. Mr. Shuster also served as EVP, Finance and Operations at Human Genome Sciences from 1992 to 1994. Prior to this, he served as EVP and then CEO of Microbiological Associates from 1986 until 1992, where he led a successful turnaround of a failing leveraged buyout and built a profitable biological testing service business today known as BioReliance. He presently serves as a board member and Audit Committee Chairman for Cleave Biosciences Inc. as well as HTG Molecular Diagnostics, Inc. He also serves as a board member of TissueNetix Inc., Active Motif Inc. and Mast Therapeutics, Inc. (NYSE MKT: MSTX)
About Response Biomedical Corp.
Response develops, manufactures and markets rapid onsite diagnostic tests for use with its RAMP® platform for clinical, biodefense and environmental applications. RAMP® represents a unique paradigm in diagnostics that provides reliable, quality results in minutes. The RAMP® Platform consists of a reader and single use disposable test cartridges and has the potential to be adapted to any other medical and nonmedical immunoassay based test currently performed in laboratories. Response clinical tests are commercially available for the aid in early detection of heart attack, congestive heart failure, thromboembolism and infectious diseases. In the nonclinical market, RAMP® tests are currently available for the environmental detection of West Nile Virus and for Biodefense applications including the rapid onsite detection of anthrax, smallpox, ricin and botulinum toxin. Response is a publicly traded company listed on the TSX under the trading symbol "RBM" and quoted on the OTC Bulletin Board under the symbol "RPBIF". For further information, please visit the Company's website at www.responsebio.com.
Response Biomedical Corp.
W.J. (Bill) Adams
Chief Financial Officer
604 456 6010
Chris Van Tuin, Chief Technologist for the Western US at Red Hat, has over 20 years of experience in IT and Software. Since joining Red Hat in 2005, he has been architecting solutions for strategic customers and partners with a focus on emerging technologies including IaaS, PaaS, and DevOps. He started his career at Intel in IT and Managed Hosting followed by leadership roles in services and sales engineering at Loudcloud and Linux startups.
Oct. 10, 2015 03:00 PM EDT Reads: 259
Saviynt Inc. has announced the availability of the next release of Saviynt for AWS. The comprehensive security and compliance solution provides a Command-and-Control center to gain visibility into risks in AWS, enforce real-time protection of critical workloads as well as data and automate access life-cycle governance. The solution enables AWS customers to meet their compliance mandates such as ITAR, SOX, PCI, etc. by including an extensive risk and controls library to detect known threats and b...
Oct. 10, 2015 03:00 PM EDT Reads: 249
Oct. 10, 2015 02:00 PM EDT Reads: 349
Oct. 10, 2015 02:00 PM EDT Reads: 306
Oct. 10, 2015 02:00 PM EDT Reads: 167
Oct. 10, 2015 02:00 PM EDT Reads: 502
Oct. 10, 2015 01:45 PM EDT Reads: 158
Oct. 10, 2015 01:00 PM EDT Reads: 244
Oct. 10, 2015 01:00 PM EDT Reads: 759
Oct. 10, 2015 01:00 PM EDT Reads: 217
Oct. 10, 2015 01:00 PM EDT Reads: 270
Oct. 10, 2015 01:00 PM EDT Reads: 165
Oct. 10, 2015 12:45 PM EDT Reads: 145
DevOps has often been described in terms of CAMS: Culture, Automation, Measuring, Sharing. While we’ve seen a lot of focus on the “A” and even on the “M”, there are very few examples of why the “C" is equally important in the DevOps equation. In her session at @DevOps Summit, Lori MacVittie, of F5 Networks, will explore HTTP/1 and HTTP/2 along with Microservices to illustrate why a collaborative culture between Dev, Ops, and the Network is critical to ensuring success.
Oct. 10, 2015 12:00 PM EDT Reads: 195
Oct. 10, 2015 12:00 PM EDT Reads: 128